Compass Therapeutics, Inc. CMPX NASDAQ

Compass Therapeutics, Inc. (CMPX) generated $-49.14M in operating cash flow for fiscal year 2025. After capital expenditures of $25K, free cash flow was $-49.17M.

Cash conversion ratio was 0.74x, suggesting some earnings are non-cash.

Criteria supported by this page:

• HEALTH (100/100, Pass) — demonstrate the company can comfortably service its debt
• MOAT (52/100, Partial) — cash flow generation is present but not at levels indicating a wide moat
• INCOME (?/100) — Cash conversion ratio was 0.74x suggests some earnings are non-cash items

Overall SharesGrow Score: 59/100 with 3/7 criteria passed.